Immunohistochemistry of DNA Mismatch Repair Enzyme MSH2 Is Not Correlated with Prognostic Data from Endometrial Carcinomas

被引：0
作者：
Schroeer, Andreas [1 ]
Koester, Frank [1 ]
Fischer, Dorothea [1 ]
Dubitscher, Ralph Martin [2 ]
Woll-Hermann, Astrid [2 ]
Diedrich, Klaus [1 ]
Friedrich, Michael [3 ]
Salehin, Darius [3 ]
机构：
[1] Med Univ Lubeck, Dept Gynecol & Obstet, D-23538 Lubeck, Germany
[2] Saarland Univ Hosp, Dept Gynecol & Obstet, D-66421 Homburg, Germany
[3] HELIOS Hosp Krefeld, Dept Gynecol & Obstet, D-47805 Krefeld, Germany
来源：
ANTICANCER RESEARCH | 2009年 / 29卷 / 11期
关键词：
Endometrial cancer; DNA mismatch repair; MSH2; immunohistochemistry; HUMAN MUT-S-HOMOLOGON-2; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; PROMOTER REGION; MUTS HOMOLOG; GENE HMSH2; EXPRESSION; P53; CISPLATIN; PROTEINS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The human Mut-S-homolog-2 (MSH2) is part of the DNA mismatch repair system (MMR). Mutations in genes of the MMR are a predisposition to hereditary non-polyposis colorectal cancer (HNPCC). In women, MMR gene mutations may lead to primary endometrial cancer (EC). The important function of the MMR for the integrity of the DNA during replication makes it probable that the MMR might also be involved in the development and the course of sporadic carcinomas. Insufficient MMR activity or expression levels could be prognostic markers of the disease. Patients and Methods: Immunohistochemical analysis of MSH2 was performed in 86 tumor samples from patients with EC. Results: Compared to known tumor markers, namely estrogen and progesterone receptors, histopathological grading, TNM stage and FIGO classification, no significant correlation between MSH2 immunoreactivity and EC was found. Conclusion: MSH2 immunohistochemical analysis is not of prognostic value for endometrial carcinoma.
引用
收藏
页码：4833 / 4837
页数：5
相关论文
共 34 条
[1]   CLUES TO THE PATHOGENESIS OF FAMILIAL COLORECTAL-CANCER [J].
AALTONEN, LA ;
PELTOMAKI, P ;
LEACH, FS ;
SISTONEN, P ;
PYLKKANEN, L ;
MECKLIN, JP ;
JARVINEN, H ;
POWELL, SM ;
JEN, J ;
HAMILTON, SR ;
PETERSEN, GM ;
KINZLER, KW ;
VOGELSTEIN, B ;
DELACHAPELLE, A .
SCIENCE, 1993, 260 (5109) :812-816
[2]  
AAMIO M, 1999, INT J CANCER, V81, P214
[3]   Microsatellite instability in hereditary and sporadic breast cancers [J].
Adem, C ;
Soderberg, CL ;
Cunningham, JM ;
Reynolds, C ;
Sebo, TJ ;
Thibodeau, SN ;
Hartmann, LC ;
Jenkins, RB .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (04) :580-582
[4]   The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study [J].
Athanassiadou, P. ;
Athanassiades, P. ;
Grapsa, D. ;
Gonidi, M. ;
Athanassiadou, A. M. ;
Stamati, P. N. ;
Patsouris, E. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (03) :697-704
[5]  
CHINTAMANI JBP, 2007, INT SEMIN SURG ONCOL, V4, P5
[6]   Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents [J].
Christmann, M ;
Kaina, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (46) :36256-36262
[7]   Immunohistochemical expression of DNA mismatch repair (MMR) system proteins (hMLH1, hMSH2) in cervical preinvasive and invasive lesions [J].
Ciavattini, A ;
Piccioni, M ;
Tranquilli, AL ;
Filosa, A ;
Pieramici, T ;
Goteri, G .
PATHOLOGY RESEARCH AND PRACTICE, 2005, 201 (01) :21-25
[8]   Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells [J].
Claij, N ;
Riele, HT .
ONCOGENE, 2004, 23 (01) :260-266
[9]   MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability [J].
Clodfelter, JE ;
Gentry, MB ;
Drotschmann, K .
NUCLEIC ACIDS RESEARCH, 2005, 33 (10) :3323-3330
[10]   Improved survival with an intact DNA mismatch repair system in endometrial cancer [J].
Cohn, David E. ;
Frankel, Wendy L. ;
Resnick, Kimberly E. ;
Zanagnolo, Vanna L. ;
Copeland, Larry J. ;
Hampel, Heather ;
Kelbick, Nicole ;
Morrison, Carl D. ;
Fowler, Jeffrey M. .
OBSTETRICS AND GYNECOLOGY, 2006, 108 (05) :1208-1215
1234